Literature DB >> 27500363

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.

Seong Joon Ahn1, Hye Kyoung Hong2, Young Mi Na2, Sang Jun Park3, Jeeyun Ahn4, Jaeseong Oh5, Jae Yong Chung6, Kyu Hyung Park3, Se Joon Woo7.   

Abstract

The intraocular route of drug administration enables the delivery of high concentrations of therapeutic drugs, while minimizing their systemic absorption. Several drugs are administered into the anterior chamber or vitreous, and the intraocular injection has been effective in curing various intraocular diseases. Rabbit eyes have been widely used for ophthalmic research, as the animal is easy to handle and economical compared to other mammals, and the size of a rabbit eye is similar to that of a human eye. Using a 30 G needle, drugs can be injected into the intracameral and intravitreal spaces of rabbit eyes. The eyeballs are then frozen until analysis, and can be divided into the aqueous humor, vitreous, and retina/choroid. The vitreous and retina/choroid samples can be homogenized and solubilized before analysis. Then, immunoassays can be performed to measure the concentrations of intraocular drugs in each compartment. Appropriate pharmacokinetic models can be used to calculate several parameters, such as the half-life and maximum concentration of the drug. Rabbit eyes can be a good model for pharmacokinetic studies of intraocular drugs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27500363      PMCID: PMC5091672          DOI: 10.3791/53878

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  42 in total

Review 1.  Drug delivery for posterior segment eye disease.

Authors:  D H Geroski; H F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-04       Impact factor: 4.799

2.  Aqueous humor dynamics in the aging human eye.

Authors:  C B Toris; M E Yablonski; Y L Wang; C B Camras
Journal:  Am J Ophthalmol       Date:  1999-04       Impact factor: 5.258

3.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

4.  Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique.

Authors:  P M Hughes; R Krishnamoorthy; A K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  1996       Impact factor: 2.671

5.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

6.  A schematic eye for the rat.

Authors:  A Hughes
Journal:  Vision Res       Date:  1979       Impact factor: 1.886

7.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

8.  Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.

Authors:  S J Park; J Oh; Y-K Kim; J H Park; J Y Park; H K Hong; K H Park; J-E Lee; H M Kim; J Y Chung; S J Woo
Journal:  Eye (Lond)       Date:  2015-01-16       Impact factor: 3.775

9.  Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.

Authors:  Colin A McCannel
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

10.  Intraocular kinetics of ceftazidime (Modacin).

Authors:  K Mochizuki; Y Yamashita; M Torisaki; M Komatsu; T Tanahashi; K Kawasaki
Journal:  Ophthalmic Res       Date:  1992       Impact factor: 2.892

View more
  9 in total

Review 1.  Challenges and opportunities for drug delivery to the posterior of the eye.

Authors:  Fernando J Cabrera; Daniel C Wang; Kartik Reddy; Ghanashyam Acharya; Crystal S Shin
Journal:  Drug Discov Today       Date:  2019-06-05       Impact factor: 7.851

2.  Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.

Authors:  Nader Sheibani; Ismail S Zaitoun; Shoujian Wang; Soesiawati R Darjatmoko; Andrew Suscha; Yong-Seok Song; Christine M Sorenson; Victor Shifrin; Daniel M Albert; Ignacio Melgar-Asensio; Irawati Kandela; Jack Henkin
Journal:  Exp Eye Res       Date:  2020-04-06       Impact factor: 3.467

3.  Scleral ultrastructure and biomechanical changes in rabbits after negative lens application.

Authors:  Xiao Lin; Bing-Jie Wang; Yen-Chiao Wang; Ren-Yuan Chu; Jin-Hui Dai; Xing-Tao Zhou; Xiao-Mei Qu; Hong Liu; Hao Zhou
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

Review 4.  Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.

Authors:  Hyeong Min Kim; Se Joon Woo
Journal:  Pharmaceutics       Date:  2021-01-15       Impact factor: 6.321

Review 5.  Gene Editing in Rabbits: Unique Opportunities for Translational Biomedical Research.

Authors:  Jie Xu; Jifeng Zhang; Dongshan Yang; Jun Song; Brooke Pallas; Chen Zhang; Jiafen Hu; Xuwen Peng; Neil D Christensen; Renzhi Han; Y Eugene Chen
Journal:  Front Genet       Date:  2021-01-28       Impact factor: 4.599

6.  Enzymatic vitreolysis using reengineered Vibrio mimicus-derived collagenase.

Authors:  Mithun Santra; Maryada Sharma; Deeksha Katoch; Sahil Jain; Uma Nahar Saikia; Mangat R Dogra; Manni Luthra-Guptasarma
Journal:  Mol Vis       Date:  2021-04-01       Impact factor: 2.367

7.  Determination of naphazoline HCl, pheniramine maleate and their official impurities in eye drops and biological fluid rabbit aqueous humor by a validated LC-DAD method.

Authors:  Khadiga M Kelani; Maha A Hegazy; Amal M Hassan; Mahmoud A Tantawy
Journal:  RSC Adv       Date:  2021-02-10       Impact factor: 3.361

8.  Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab.

Authors:  Patricia Muñoz-Villegas; Alejandra Sanchez-Rios; Mayra G Quinonez-Alvarado; Oscar Olvera-Montaño; Juan D Quintana-Hau; Leopoldo Baiza-Duran
Journal:  J Exp Pharmacol       Date:  2021-05-31

9.  Trans-Ocular Electric Current In Vivo Enhances AAV-Mediated Retinal Transduction in Large Animal Eye After Intravitreal Vector Administration.

Authors:  Hongman Song; Yong Zeng; Sheik Pran Babu Sardar Pasha; Ronald A Bush; Camasamudram Vijayasarathy; Haohua Qian; Lisa Wei; Henry E Wiley; Zhijian Wu; Paul A Sieving
Journal:  Transl Vis Sci Technol       Date:  2020-06-24       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.